高级检索
当前位置: 首页 > 详情页

Combining the systemic inflammation response index and prognostic nutritional index to predict the prognosis of locally advanced elderly esophageal squamous cell carcinoma patients undergoing definitive radiotherapy

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Dept Radiat Oncol, Hosp 4, Shijiazhuang 05000, Hebei, Peoples R China [2]Hebei Gen Hosp, Dept Neurol, Shijiazhuang, Hebei, Peoples R China [3]Hebei Med Univ, Dept Resp Med, Hosp 4, Shijiazhuang, Hebei, Peoples R China
出处:
ISSN:

关键词: Esophageal squamous cell carcinoma (ESCC) elderly radiotherapy systemic inflammation response index (SIRI) prognostic nutritional index (PNI)

摘要:
Background: The systemic inflammation response index (SIRI) and prognostic nutritional index (PNI) have been shown to be correlated with the prognosis of various solid tumors. This study sought to investigate the prognostic value of the SIRI and the PNI individually and in combination in locally advanced elderly esophageal squamous cell carcinoma (ESCC) patients treated with radical radiotherapy. Methods: The data of 192 ESCC patients aged >= 65 years, who had been treated with definitive radiotherapy between 2013 and 2016, were retrospectively analyzed. The optimal cutoff values of SIRI and PNI were determined by receiver operating characteristic curves. Kaplan-Meier curves and Cox proportional hazards models were used to analyze the effect of the SIRI and PNI on overall survival (OS) and progressionfree survival (PFS). The areas under the curve were measured to evaluate the predictive ability of the SIRI, PNI, and SIRI combined with PNI for OS. Results: The optimal cutoff values of the pretreatment SIRI and PNI were 1.03 and 49.60, respectively. The univariate and multivariate analyses demonstrated that T stage (P=0.021), TNM stage (P=0.022), synchronous chemotherapy (P=0.032), the SIRI (P=0.001), and the PNI (P=0.045) were independent prognostic factors for OS and N stage (P=0.004), synchronous chemotherapy (P=0.016) and the SIRI (P=0.004) were independent prognostic factors for PFS. The AUC of the combined SIRI and PNI (0.706; 0.612-0.801) was higher than those of the SIRI (0.648; 0.540-0.756) and the PNI (0.621; 0.523-0.720). Patients in the low-SIRI and high-PNI groups, especially those in clinical stage II or who received synchronous chemotherapy (P<0.001, P=0.002), had better OS and PFS than those in the other groups Conclusions: The SIRI and PNI are simple and reliable biomarkers for predicting long-term survival in elderly patients with locally advanced ESCC after radical radiotherapy. A high SIRI and a low PNI indicated poor prognosis, and the combination of the SIRI and PNI improved the accuracy of prognosis prediction and could be used to guide individualized treatment of patients.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2022]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 胃肠肝病学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 胃肠肝病学 4 区 肿瘤学
JCR分区:
出版当年[2022]版:
Q4 GASTROENTEROLOGY & HEPATOLOGY Q4 ONCOLOGY
最新[2023]版:
Q3 GASTROENTEROLOGY & HEPATOLOGY Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Dept Radiat Oncol, Hosp 4, Shijiazhuang 05000, Hebei, Peoples R China
通讯作者:
通讯机构: [1]Hebei Med Univ, Dept Radiat Oncol, Hosp 4, Shijiazhuang 05000, Hebei, Peoples R China [*1]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Combining the systemic inflammation response index and prognostic nutritional index to predict the prognosis of locally advanced elderly esophageal squamous cell carcinoma patients undergoing definitive radiotherapy [2]Predictive effect of the systemic inflammation response index (SIRI) on the efficacy and prognosis of neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer [3]The genetic profiles of esophageal squamous cell carcinoma (ESCC) in Hebei, a northern province of China [4]The microbial characteristics of esophageal squamous cell carcinoma (ESCC) and healthy subjects [5]Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC) [6]Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial [7]Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study [8]Camrelizumab combined with albumin paclitaxel and cisplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESCC). [9]Clinical Outcomes in Different Irradiation Volume for Esophageal Squamous Cell Carcinoma (ESCC) in Definitive Intensity-Modulated Radiotherapy (IMRT) Combined with Concurrent Chemotherapy [10]Simultaneous Integrated Boost Intensity-Modulated Radiotherapy (SIB-IMRT) Combined with Nimotuzumab for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC): A Phase II Clinical Trial

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号